Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Core Viewpoint - Syros Pharmaceuticals, Inc. (SYRS) has experienced a significant decline of 70.6% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Stock Performance and Technical Indicators - The stock's Relative Strength Index (RSI) reading is at 20.05, indicating that the heavy selling pressure may be exhausting, which could lead to a price rebound [5]. - A stock is generally considered oversold when its RSI falls below 30, making the current RSI reading a potential signal for investors to look for entry opportunities [2][3]. Group 2: Earnings Estimates and Analyst Consensus - Over the last 30 days, the consensus earnings per share (EPS) estimate for SYRS has increased by 3.2%, indicating a positive trend in earnings revisions that typically correlates with price appreciation [5]. - SYRS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [6].